(Q40992057)

English

Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic

scientific article published on 30 April 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 September 2017

Risk of overall mortality and cardiovascular events in patients with type 2 diabetes on dual drug therapy including metformin: A large database study from the Cleveland Clinic (English)

1 reference

Europe PubMed Central

25 September 2017

type 2 diabetes

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Subramanian Kannan

1

1 reference

Europe PubMed Central

25 September 2017

Kevin M Pantalone

2

1 reference

Europe PubMed Central

25 September 2017

Simone Matsuda

3

1 reference

Europe PubMed Central

25 September 2017

Brian J Wells

4

1 reference

Europe PubMed Central

25 September 2017

Matthew Karafa

5

1 reference

Europe PubMed Central

25 September 2017

Robert S Zimmerman

6

1 reference

Europe PubMed Central

25 September 2017

publication date

30 April 2015

1 reference

Europe PubMed Central

25 September 2017

Journal of diabetes

1 reference

Europe PubMed Central

25 September 2017

8

1 reference

Europe PubMed Central

25 September 2017

2

1 reference

Europe PubMed Central

25 September 2017

279-285

1 reference

Europe PubMed Central

25 September 2017

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

AACE comprehensive diabetes management algorithm 2013.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Sulfonylureas and prognosis after myocardial infarction in patients with diabetes: a population-based follow-up study.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08).

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Results of a reevaluation of cardiovascular outcomes in the RECORD trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Sitagliptin use in patients with diabetes and heart failure: a population-based retrospective cohort study

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study.

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Development and validation of an electronic health record-based chronic kidney disease registry

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1111%2F1753-0407.12301

21 January 2018

Identifiers

10.1111/1753-0407.12301

1 reference

Europe PubMed Central

25 September 2017

release_laninjtf6nbf5lj2udwoktd5rm

1 reference

https://api.fatcat.wiki/v0/release/laninjtf6nbf5lj2udwoktd5rm

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

25 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40992057&oldid=2092898946"